Transient downregulation of monocyte-derived dendritic-cell differentiation, function, and survival during tumoral progression and regression in an in vivo canine model of transmissible venereal tumor.
Tumors often target dendritic cells (DCs) to evade host immune surveillance. DC injury is reported in many rodent and human tumors but seldom in tumors of other mammals. Canine transmissible venereal tumor (CTVT), a unique and spontaneous cancer transmitted by means of viable tumor cells. CTVT causes manifold damage to monocyte-derived DCs. This cancer provides an in vivo model of cancer to study the role of monocyte-derived DCs during spontaneous regression. Using flow cytometry and real-time reverse-transcription polymerase chain reactions, we compared the expression of surface molecules on monocyte-derived DCs between normal dogs and dogs with CTVT. These markers were CD1a, CD83, costimulatory factors (CD40, CD80, and CD86), and major histocompatability complex classes I and II. In immature DCs (iDCs) and lipopolysaccharide-treated mature DCs (mDCs), the surface markers were mostly downregulated during tumoral progression and regression. The tumor lowered endocytic activity of iDCs, as reflected in dextran uptake, and decreased allogeneic mixed lymphocyte reactions of mDCs. In addition, it decreased the number of monocytes in the peripheral blood by 40%. The tumor substantially impaired the efficiency with which DCs were generated from monocytes and with which mDCs were generated from iDCs. We also found that progression-phase CTVT supernatants that were cultured for 48 h and that contained protein components killed both monocytes and DCs. Additionally, DC numbers were significantly lower in the draining lymph nodes in CTVT dogs than in normal dogs. In conclusion, CTVT caused devastating damage to monocyte-derived DCs; this might be one of its mechanisms for evading host immunity. Reestablishment of monocyte-derived DC activity by the host potentially might contribute to spontaneous tumoral regression. These findings provide insight into the extent of tumoral effects on host immune systems and responses. This information is useful for developing cancer immunotherapies.
Liu
Cheng-Chi
CC
Department of Veterinary Medicine, Animal Cancer Research Center, National Taiwan University, 1, Roosevelt Road, Section 4, 106 Taipei, Taiwan, ROC.
Wang
Yu-Shan
YS
Lin
Ching-Yi
CY
Chuang
Tien-Fu
TF
Liao
Kuang-Wen
KW
Chi
Kwan-Hwa
KH
Chen
Mo-Fan
MF
Chiang
Hsin-Chien
HC
Chu
Rea-Min
RM
D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis; D002454:Cell Differentiation / Q000502:physiology; D002470:Cell Survival / Q000502:physiology; D003713:Dendritic Cells / Q000166:cytology* / Q000378:metabolism*; D004195:Disease Models, Animal; D018450:Disease Progression; D004283:Dog Diseases; D004285:Dogs; D015536:Down-Regulation; D005434:Flow Cytometry; D006649:Histocompatibility Antigens / Q000096:biosynthesis; D006801:Humans; D007959:Lymphocyte Culture Test, Mixed; D016246:Lymphocytes, Tumor-Infiltrating; D009000:Monocytes / Q000166:cytology* / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019139:Tumor Escape / Q000276:immunology*; D014685:Venereal Tumors, Veterinary / Q000276:immunology* / Q000503:physiopathology
D015703:Antigens, CD; D006649:Histocompatibility Antigens
Int Immunol. 2000 Nov;12(11):1511-9
11058570
Exp Biol Med (Maywood). 2006 Apr;231(4):431-43
16565439
J Periodontal Res. 2002 Jun;37(3):177-83
12113551
Cancer Immunol Immunother. 2004 Dec;53(12):1093-100
15696609
Semin Cancer Biol. 2002 Feb;12(1):33-42
11926410
J Immunol. 2002 Mar 1;168(5):2255-63
11859113
Nat Med. 2006 Feb;12(2):214-9
16444265
J Exp Med. 2002 Feb 4;195(3):343-51
11828009
Methods. 2001 Dec;25(4):402-8
11846609
J Immunol. 2006 May 1;176(9):5637-43
16622033
Blood. 1998 Dec 15;92(12):4778-91
9845545
Br J Cancer. 2003 Oct 20;89(8):1463-72
14562018
Int J Cancer. 2001 Dec 15;94(6):825-33
11745485
Clin Cancer Res. 2006 Jan 1;12(1):264-72
16397051
J Immunol Methods. 2004 Nov;294(1-2):67-80
15604017
Immunol Cell Biol. 2005 Oct;83(5):451-61
16174093
Vet Immunol Immunopathol. 2003 May 12;92(3-4):149-62
12730015
Can J Vet Res. 2007 Jul;71(3):165-74
17695590
Eur J Immunol. 2004 Oct;34(10):2800-11
15368296
Immunology. 1997 Feb;90(2):294-300
9135560
J Immunol. 2005 Sep 1;175(5):3045-52
16116192
J Hematother Stem Cell Res. 2003 Oct;12(5):515-23
14594508
Pathobiology. 1999;67(5-6):282-6
10725803
Curr Opin Immunol. 1997 Feb;9(1):10-6
9039784
Adv Exp Med Biol. 1997;417:525-8
9286414
Immunol Lett. 1992 Feb;31(2):189-97
1371267
J Immunol. 2004 Feb 1;172(3):1508-14
14734728
Vet Immunol Immunopathol. 2006 Jan 15;109(1-2):167-76
16202456
Biochemistry. 1983 Dec 6;22(25):5692-8
6607069
J Hepatol. 1999 Aug;31(2):323-31
10453947
J Immunol. 2000 Feb 1;164(3):1269-76
10640740
Vet Immunol Immunopathol. 2002 Aug;87(1-2):19-27
12052339
Anticancer Res. 2001 Nov-Dec;21(6A):4017-24
11911286
Science. 1990 Sep 21;249(4975):1431-3
1698311
Mod Pathol. 2001 Jan;14(1):40-5
11211308
Adv Cancer Res. 1985;43:75-112
3887857
Mol Immunol. 2005 Aug;42(12):1531-40
15950746
Clin Immunol. 2004 Dec;113(3):310-7
15507396
Cancer Immunol Immunother. 2007 Jan;56(1):48-59
16612596
Vet Rec. 1969 Apr 19;84(16):418-9
5815470
Transplantation. 2000 Nov 27;70(10):1437-42
11118086
Cell. 2006 Aug 11;126(3):477-87
16901782
Anticancer Res. 2004 Jul-Aug;24(4):2243-8
15330168
Annu Rev Immunol. 2000;18:767-811
10837075
Blood. 2001 Dec 15;98(13):3750-6
11739182
Cancer Immunol Immunother. 2004 Jun;53(6):543-50
14666382
Eur J Immunol. 2006 Jun;36(6):1537-47
16708404
Prostate. 2001 Jan 1;46(1):68-75
11170134
J Immunol. 2004 Aug 1;173(3):1772-8
15265907